STSA News and Press, Satsuma Pharmaceuticals Inc. From 11/14/22

STS101 was not statistically superior to placebo at two hours post-administration on the co-primary endpoints of freedom from pain and most bothersome symptom STS101 showed superiority (p<0.001) differences versus placebo on freedom from pain and most bothersome symptom at al...

Satsuma Pharmaceuticals press release ( NASDAQ: STSA ): Q3 GAAP EPS of -$0.48. As of September 30, 2022, Satsuma had $64.4 million in combined cash, cash equivalents and marketable securities, which it believes is sufficient to fund operations into the second half of 2023 ...

- On track to report topline results from STS101 SUMMIT Phase 3 efficacy trial in November 2022; NDA submission planned in Q1 2023 - - $64.4 million in cash, cash equivalents and marketable securities as of September 30, 2022, provides runway into second half of 2023 - S...

Satsuma Pharmaceuticals ( NASDAQ: STSA ) stock rose ~11% on Oct. 10 after SVB Securities upgraded the company's shares to Outperform from Market Perform and raised the price target to $15 from $5. South San Francisco, Calif.-based company is developing ...

Satsuma Pharmaceuticals ( NASDAQ: STSA ) stock rose ~5% on Sept. 20 after the company said STS101 showed a favorable safety and tolerability profile in an ongoing phase 3 trial in patients with migraine. STS101 is a nasal powder formulation of ant...

STS101 demonstrated a favorable safety and tolerability profile, consistent with clinical experience to date Over 8,000 migraine attacks treated with more than 10,000 doses of STS101; of which, over 5,500 migraine attacks treated with more than 6,900 doses of STS101 M ...

South San Francisco, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatme...

Satsuma Pharmaceuticals press release ( NASDAQ: STSA ): Q2 GAAP EPS of -$0.52. $68.1 million in cash, cash equivalents and marketable securities as of June 30, 2022, provides runway into second half of 2023 For further details see: Satsuma Pharmaceuticals GAAP EP...

- Completed enrollment in the SUMMIT pivotal Phase 3 efficacy trial of STS101, randomizing more than 1,400 subjects - - On track to announce SUMMIT trial topline results in Q4 2022 - - Completed STS101 clinical and CMC pre-NDA meetings with FDA - - Presented nine...

- More than 1,400 subjects randomized - - Satsuma expects to announce topline SUMMIT trial results in Q4 2022 - SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company deve...